Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China (Q90682026)
Jump to navigation
Jump to search
scientific article published on 30 September 2019
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China |
scientific article published on 30 September 2019 |
Statements
Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China (English)
Xiaoyuan Xu
Bo Feng
Yujuan Guan
Sujun Zheng
Jifang Sheng
Xingxiang Yang
Yuanji Ma
Yan Huang
Yi Kang
Xiaofeng Wen
Jun Li
Youwen Tan
Qing He
Qing Xie
Maorong Wang
Ping An
Guozhong Gong
Huimin Liu
Qin Ning
Rui Hua
Bo Ning
Wen Xie
Jiming Zhang
Wenxiang Huang
Yongfeng Yang
Minghua Lin
Yingren Zhao
Yanhong Yu
Jidong Jia
Dongliang Yang
Liang Chen
Yinong Ye
Yuemin Nan
Zuojiong Gong
Quan Zhang
Peng Hu
Fusheng Wang
Yongguo Li
Dongliang Li
Zhansheng Jia
Jinlin Hou
Chengwei Chen
Jinzi J Wu
30 September 2019
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference